

Takayuki Ohkuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5693110/publications.pdf>

Version: 2024-02-01

30
papers

994
citations

567281

15
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

1783
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2021619.	4.6	19
2	A tumor metastasis-associated molecule <i>TWIST1</i> is a favorable target for cancer immunotherapy due to its immunogenicity. <i>Cancer Science</i> , 2022, 113, 2526-2535.	3.9	4
3	A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2301-2312.	4.2	11
4	Prognostic significance of OX40 ⁺ lymphocytes in tumor stroma of surgically resected small-cell lung cancer. <i>Oncolmmunology</i> , 2021, 10, 1971430.	4.6	2
5	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3421-3434.	4.2	11
6	IFN- γ - and IL-17-producing CD8 ⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. , 2021, 9, e002426.		8
7	A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. <i>Cancer Science</i> , 2021, 112, 2705-2713.	3.9	6
8	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
9	Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1856545.	4.6	13
10	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 408-414.	2.1	19
11	Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 989-999.	4.2	15
12	Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. <i>Laboratory Investigation</i> , 2019, 99, 612-624.	3.7	12
13	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	4.4	13
14	Innovative immunotherapy for nasal NK/T-cell lymphoma. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2018, 36, 15-22.	0.0	0
15	Effects of STING stimulation on macrophages: STING agonists polarize into "classically" or "alternatively" activated macrophages?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 285-287.	3.3	29
16	Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1466771.	4.6	14
17	Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 705-716.	4.2	128
18	Intratumoral injection of IFN- γ induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 521-527.	2.1	15

#	ARTICLE	IF	CITATIONS
19	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 877-890.	4.2	126
20	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1169356.	4.6	34
21	Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 16280.	3.3	22
22	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 549-554.	2.1	26
23	c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. <i>Oncolimmunology</i> , 2015, 4, e976077.	4.6	35
24	Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. <i>Oncolimmunology</i> , 2015, 4, e999523.	4.6	16
25	STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2014, 2, 1199-1208.	3.4	185
26	Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. <i>Immunology Letters</i> , 2014, 158, 175-182.	2.5	9
27	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. <i>Immunology Letters</i> , 2014, 161, 20-30.	2.5	24
28	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRVIII chimeric antigen receptor in mice bearing human GBM xenografts. , 2013, 1, 21.		85
29	First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. <i>Cancer Science</i> , 2012, 103, 150-153.	3.9	53
30	IFN- γ -dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. <i>Carcinogenesis</i> , 2009, 30, 1408-1415.	2.8	33